Currently under review in the U.S. for a rare genetic disorder, the drug is seen by some investors as critical to Biohaven’s ...

Shares of Biohaven ( BHVN 5.24%) are surging on Monday. The company's stock was up about 8% as of midday trading and had ...

Oberland Capital Management is pumping some new life into Biohaven, striking a unique investment deal worth up to $600 ...

Biohaven will use the money to bankroll commercial preparations for the spinocerebellar ataxia drug candidate troriluzole, ...

Biohaven Ltd. on Monday announced that New York-based Oberland Capital has agreed to invest up to $600 million in the New ...

Stemchymal ® is an allogeneic adipose-derived mesenchymal stem cell (MSC) therapy developed for spinocerebellar ataxia (SCA), a rare neurodegenerative disease that is currently incurable.

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the ...

Biohaven Ltd. (BHVN) shares rise premarket as it secures up to $600 million investment from Oberland Capital. Cash reserves ...